Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.05 Million USD | -28.43% |
| 2022 | -15.61 Million USD | -9.42% |
| 2021 | -14.26 Million USD | -59.24% |
| 2020 | -8.96 Million USD | -21.23% |
| 2019 | -7.39 Million USD | -73.22% |
| 2018 | -4.26 Million USD | -11.02% |
| 2017 | -3.84 Million USD | 8.62% |
| 2016 | -4.2 Million USD | -74.75% |
| 2015 | -2.4 Million USD | -328.01% |
| 2014 | -562.31 Thousand USD | -267.03% |
| 2013 | 336.64 Thousand USD | 113.76% |
| 2012 | 157.49 Thousand USD | 312.08% |
| 2011 | -74.25 Thousand USD | -525.8% |
| 2010 | -11.86 Thousand USD | 94.09% |
| 2009 | -200.93 Thousand USD | 16.09% |
| 2008 | -239.47 Thousand USD | -223.65% |
| 2007 | 193.66 Thousand USD | 521.91% |
| 2006 | -45.9 Thousand USD | 59.24% |
| 2005 | -112.61 Thousand USD | 59.62% |
| 2004 | -278.91 Thousand USD | -425.82% |
| 2003 | 85.6 Thousand USD | -56.62% |
| 2002 | 197.35 Thousand USD | 932.33% |
| 2001 | -23.71 Thousand USD | 91.82% |
| 2000 | -289.83 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.63 Million USD | -10.3% |
| 2024 Q1 | -5.1 Million USD | 9.45% |
| 2023 FY | -20.05 Million USD | -28.43% |
| 2023 Q1 | -5 Million USD | -0.69% |
| 2023 Q2 | -4.63 Million USD | 7.47% |
| 2023 Q4 | -5.64 Million USD | -18.35% |
| 2023 Q3 | -4.76 Million USD | -2.9% |
| 2022 Q1 | -2.93 Million USD | -5.05% |
| 2022 FY | -15.61 Million USD | -9.42% |
| 2022 Q4 | -4.97 Million USD | -17.04% |
| 2022 Q3 | -4.24 Million USD | -22.93% |
| 2022 Q2 | -3.45 Million USD | -17.77% |
| 2021 Q3 | -3.85 Million USD | -7.18% |
| 2021 Q2 | -3.6 Million USD | 10.82% |
| 2021 FY | -14.26 Million USD | -59.24% |
| 2021 Q1 | -4.03 Million USD | -50.56% |
| 2021 Q4 | -2.79 Million USD | 27.62% |
| 2020 Q2 | -2.2 Million USD | 16.66% |
| 2020 FY | -8.96 Million USD | -21.23% |
| 2020 Q3 | -1.43 Million USD | 34.78% |
| 2020 Q4 | -2.68 Million USD | -86.73% |
| 2020 Q1 | -2.64 Million USD | -0.16% |
| 2019 Q1 | -1.9 Million USD | -39.46% |
| 2019 Q3 | -1.62 Million USD | -18.85% |
| 2019 Q4 | -2.63 Million USD | -61.97% |
| 2019 FY | -7.39 Million USD | -73.22% |
| 2019 Q2 | -1.37 Million USD | 28.17% |
| 2018 Q1 | -814.37 Thousand USD | 41.2% |
| 2018 Q3 | -789.75 Thousand USD | 39.0% |
| 2018 Q4 | -1.36 Million USD | -73.21% |
| 2018 FY | -4.26 Million USD | -11.02% |
| 2018 Q2 | -1.29 Million USD | -58.99% |
| 2017 Q2 | -830.85 Thousand USD | 16.12% |
| 2017 Q1 | -990.49 Thousand USD | -19.61% |
| 2017 Q4 | -1.38 Million USD | -117.47% |
| 2017 FY | -3.84 Million USD | 8.62% |
| 2017 Q3 | -636.89 Thousand USD | 23.34% |
| 2016 Q4 | -828.13 Thousand USD | 48.59% |
| 2016 Q1 | -733.05 Thousand USD | 21.32% |
| 2016 FY | -4.2 Million USD | -74.75% |
| 2016 Q2 | -1.06 Million USD | -45.61% |
| 2016 Q3 | -1.61 Million USD | -50.9% |
| 2015 Q2 | -352.36 Thousand USD | 7.89% |
| 2015 Q1 | -382.53 Thousand USD | -23.42% |
| 2015 Q4 | -931.67 Thousand USD | -25.87% |
| 2015 FY | -2.4 Million USD | -328.01% |
| 2015 Q3 | -740.18 Thousand USD | -110.06% |
| 2014 FY | -562.31 Thousand USD | -267.03% |
| 2014 Q1 | 158.23 Thousand USD | 250.0% |
| 2014 Q4 | -309.94 Thousand USD | -56.8% |
| 2014 Q3 | -197.67 Thousand USD | 7.17% |
| 2014 Q2 | -212.93 Thousand USD | -234.57% |
| 2013 Q3 | -103.01 Thousand USD | -127.87% |
| 2013 Q4 | -105.49 Thousand USD | -2.41% |
| 2013 Q2 | 369.64 Thousand USD | 109.42% |
| 2013 Q1 | 176.5 Thousand USD | 4.38% |
| 2013 FY | 336.64 Thousand USD | 113.76% |
| 2012 Q3 | -28.62 Thousand USD | 51.72% |
| 2012 Q4 | 169.1 Thousand USD | 690.75% |
| 2012 Q2 | -59.29 Thousand USD | -177.7% |
| 2012 Q1 | 76.3 Thousand USD | 157.54% |
| 2012 FY | 157.49 Thousand USD | 312.08% |
| 2011 FY | -74.25 Thousand USD | -525.8% |
| 2011 Q1 | -4427.00 USD | -106.4% |
| 2011 Q2 | 40.75 Thousand USD | 1020.69% |
| 2011 Q3 | 22.03 Thousand USD | -45.95% |
| 2011 Q4 | -132.62 Thousand USD | -701.97% |
| 2010 Q3 | -14.13 Thousand USD | -155.46% |
| 2010 Q1 | -99.7 Thousand USD | 39.27% |
| 2010 FY | -11.86 Thousand USD | 94.09% |
| 2010 Q2 | 25.47 Thousand USD | 125.55% |
| 2010 Q4 | 69.2 Thousand USD | 589.79% |
| 2009 Q3 | 29.94 Thousand USD | 342.73% |
| 2009 FY | -200.93 Thousand USD | 16.09% |
| 2009 Q1 | -54.38 Thousand USD | 56.78% |
| 2009 Q2 | -12.33 Thousand USD | 77.31% |
| 2009 Q4 | -164.16 Thousand USD | -648.21% |
| 2008 Q1 | -86.6 Thousand USD | -276.37% |
| 2008 Q4 | -125.81 Thousand USD | -1415.08% |
| 2008 Q3 | -8304.00 USD | 55.72% |
| 2008 Q2 | -18.75 Thousand USD | 78.35% |
| 2008 FY | -239.47 Thousand USD | -223.65% |
| 2007 Q3 | 64.12 Thousand USD | -22.08% |
| 2007 FY | 193.66 Thousand USD | 521.91% |
| 2007 Q4 | 49.1 Thousand USD | -23.42% |
| 2007 Q2 | 82.29 Thousand USD | 4548.27% |
| 2007 Q1 | -1850.00 USD | -103.11% |
| 2006 Q2 | -19.47 Thousand USD | 10.41% |
| 2006 FY | -45.9 Thousand USD | 59.24% |
| 2006 Q4 | 59.45 Thousand USD | 192.68% |
| 2006 Q3 | -64.14 Thousand USD | -229.4% |
| 2006 Q1 | -21.73 Thousand USD | 91.64% |
| 2005 FY | -112.61 Thousand USD | 59.62% |
| 2005 Q1 | -4345.00 USD | -111.08% |
| 2005 Q2 | 19.05 Thousand USD | 538.48% |
| 2005 Q3 | -73.84 Thousand USD | -487.62% |
| 2005 Q4 | -259.84 Thousand USD | -251.86% |
| 2004 Q4 | 39.2 Thousand USD | 501.24% |
| 2004 FY | -278.91 Thousand USD | -425.82% |
| 2004 Q3 | 6521.00 USD | 102.18% |
| 2004 Q2 | -298.75 Thousand USD | -9143.63% |
| 2004 Q1 | -3232.00 USD | -109.1% |
| 2003 Q1 | -6602.00 USD | 75.42% |
| 2003 FY | 85.6 Thousand USD | -56.62% |
| 2003 Q4 | 35.5 Thousand USD | 13.83% |
| 2003 Q3 | 31.19 Thousand USD | 22.3% |
| 2003 Q2 | 25.5 Thousand USD | 486.34% |
| 2002 Q4 | -26.85 Thousand USD | -134.25% |
| 2002 Q2 | 48.44 Thousand USD | -50.24% |
| 2002 Q1 | 97.34 Thousand USD | 555.06% |
| 2002 Q3 | 78.42 Thousand USD | 61.91% |
| 2002 FY | 197.35 Thousand USD | 932.33% |
| 2001 Q2 | 7170.00 USD | 145.2% |
| 2001 Q1 | -15.86 Thousand USD | 84.27% |
| 2001 FY | -23.71 Thousand USD | 91.82% |
| 2001 Q4 | -21.39 Thousand USD | -15.45% |
| 2001 Q3 | -18.52 Thousand USD | -358.42% |
| 2000 Q3 | -64.54 Thousand USD | 0.0% |
| 2000 FY | -289.83 Thousand USD | 0.0% |
| 2000 Q4 | -100.85 Thousand USD | -56.26% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 87.111% |
| Theratechnologies Inc. | -10.62 Million USD | -88.671% |
| Safety Shot Inc | -12.18 Million USD | -64.559% |
| Cosmos Health Inc. | -21.83 Million USD | 8.159% |
| Cronos Group Inc. | -81.37 Million USD | 75.361% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 109.592% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 48.79% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 260.08% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -468.51% |
| ProPhase Labs, Inc. | -21.61 Million USD | 7.231% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -326.506% |
| Dynavax Technologies Corporation | -37.02 Million USD | 45.852% |
| Radius Health, Inc. | -3.92 Million USD | -410.829% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -697.15% |
| Alvotech | -354.86 Million USD | 94.35% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -318.993% |
| Alpha Teknova, Inc. | -35.56 Million USD | 43.621% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 87.42% |
| SCYNEXIS, Inc. | 72.66 Million USD | 127.591% |
| Harrow Health, Inc. | 580 Thousand USD | 3556.906% |
| Biofrontera Inc. | -22.67 Million USD | 11.584% |
| DURECT Corporation | -36.88 Million USD | 45.64% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -280.529% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 142.686% |
| OptiNose, Inc. | -22.74 Million USD | 11.86% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 258.724% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -32.764% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -222.825% |
| SIGA Technologies, Inc. | 83.62 Million USD | 123.977% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 314.876% |
| Shineco, Inc. | -17.06 Million USD | -17.486% |
| Phibro Animal Health Corporation | 53.31 Million USD | 137.607% |
| Procaps Group S.A. | 52.32 Million USD | 138.319% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -135.246% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -323.289% |
| Viatris Inc. | 766.2 Million USD | 102.617% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -318.993% |
| Rockwell Medical, Inc. | -6.67 Million USD | -200.601% |
| Incannex Healthcare Limited | -30.04 Million USD | 33.258% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -281.615% |
| Tilray Brands, Inc. | -174.74 Million USD | 88.526% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 112.009% |
| PetIQ, Inc. | 60.01 Million USD | 133.408% |
| Silver Spike Investment Corp. | 7.34 Million USD | 373.157% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 107.991% |
| Journey Medical Corporation | -2.07 Million USD | -867.2% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1263.022% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -47.239% |
| Assertio Holdings, Inc. | -243.53 Million USD | 91.767% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -240.271% |
| Embecta Corp. | 221.5 Million USD | 109.052% |
| Procaps Group, S.A. | 38.97 Million USD | 151.446% |
| PainReform Ltd. | -9.58 Million USD | -109.203% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 85.455% |
| Hempacco Co., Inc. | -8.81 Million USD | -127.524% |
| Talphera, Inc. | -16.88 Million USD | -18.717% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 122.869% |
| Alvotech | -354.86 Million USD | 94.35% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 105.499% |
| Kamada Ltd. | 10.06 Million USD | 299.226% |
| Indivior PLC | -4 Million USD | -401.251% |
| Currenc Group, Inc. | -6.64 Million USD | -201.696% |
| Evoke Pharma, Inc. | -7.43 Million USD | -169.82% |
| Flora Growth Corp. | -50.35 Million USD | 60.182% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -0.0% |
| Evolus, Inc. | -49.23 Million USD | 59.275% |
| HUTCHMED (China) Limited | 18.37 Million USD | 209.116% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 110.178% |
| Akanda Corp. | -10.05 Million USD | -99.476% |